Related references
Note: Only part of the references are listed.Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer
J. C. Osorio et al.
ANNALS OF ONCOLOGY (2017)
Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy
Gautam Kishore Valecha et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2017)
Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms
Danae A. Delivanis et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism
D. J. Stott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
Morganna Freeman-Keller et al.
CLINICAL CANCER RESEARCH (2016)
Bypassing checkpoints, overcoming resistance, and honing in on new targets
Egbert F. Smit et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies (vol 26, pg 2375, 2015)
J. Naidoo et al.
ANNALS OF ONCOLOGY (2016)
Endocrinological side-effects of immune checkpoint inhibitors
Francesco Torino et al.
CURRENT OPINION IN ONCOLOGY (2016)
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
J. M. Michot et al.
EUROPEAN JOURNAL OF CANCER (2016)
Optimal design and endpoint of clinical trials using immune checkpoint blocking agents
Bhumsuk Keam et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2016)
Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab
Jeroen de Filette et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Clinical Update in Aspects of the Management of Autoimmune Thyroid Diseases
Duncan J. Topliss
ENDOCRINOLOGY AND METABOLISM (2016)
Classifying Cancers Based on T-cell Infiltration and PD-L1
Michele W. L. Teng et al.
CANCER RESEARCH (2015)
Induction of Painless Thyroiditis in Patients Receiving Programmed Death 1 Receptor Immunotherapy for Metastatic Malignancies
Steven Orlov et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
Hansje-Eva Teulings et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Clinical characteristics and treatment-related biomarkers associated with response to high-dose interleukin-2 in metastatic melanoma and renal cell carcinoma: retrospective analysis of an academic community hospital's experience
Christine Saraceni et al.
SPRINGERPLUS (2015)
Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
Mabel Ryder et al.
ENDOCRINE-RELATED CANCER (2014)
Skin Rash could Predict the Response to EGFR Tyrosine Kinase Inhibitor and the Prognosis for Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Hong-bing Liu et al.
PLOS ONE (2013)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade
Stephanie G. Downey et al.
CLINICAL CANCER RESEARCH (2007)
Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma
GQ Phan et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
